Golimumab 2 mg/kg IV

BIOLOGICAL2 trials

Sponsors

Janssen Biotech, Inc.

Conditions

ArthritisArthritis, RheumatoidAutoimmune Diseases

Phase 3

Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)

CompletedNCT01004432

Janssen Biotech, Inc.Arthritis, Arthritis, Rheumatoid, Autoimmune Diseases

Start: 2009-12-31End: 2013-10-31Updated: 2015-04-30

A Golimumab Phase 3b, Multicenter, Assessment of Intravenous Efficacy in Rheumatoid Arthritis Subjects Who Have Diminished Disease Control Despite Treatment With Infliximab (REMICADE®)

TerminatedNCT01962974

Janssen Biotech, Inc.Arthritis, Rheumatoid

Start: 2013-10-31End: 2014-12-31Updated: 2017-04-12

Related Papers

Satisfaction with Subcutaneous Golimumab and its Auto-Injector among Rheumatoid Arthritis Patients with Inadequate Response to Adalimumab or Etanercept

Patient2018-02-0913 citations

Clinical response to golimumab in rheumatoid arthritis patients who were receiving etanercept or adalimumab: results of a multicenter active treatment study

Current Medical Research and Opinion2016-12-3012 citations